Suheung (008490) Fundamentals 2026 — P/E 4.6x, Revenue Analysis | SniperIQ
Suheung (008490) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩224.9B, trading at ₩20200.00 on the KSC. This SniperIQ fundamentals page covers Suheung's valuation (P/E 4.6x, P/B 0.4x), profitability (net margin 6.6%), revenue (₩722.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Suheung's market cap?
Suheung (008490) has a market capitalization of approximately ₩224.9B, trading at ₩20200.00 on the KSC. Market cap moves with the live share price.
What is Suheung's P/E ratio?
Suheung's trailing twelve-month P/E ratio is 4.6x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Suheung?
Suheung runs a net profit margin of 6.6%, a gross margin of 17.7%, and an operating margin of 8.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Suheung generate?
Suheung reported revenue of ₩722.3B for fiscal year 2025, with net income of ₩43.5B and earnings per share (EPS) of 3910.89. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Suheung pay a dividend?
Suheung offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Suheung financially healthy?
Suheung carries a debt-to-equity ratio of 0.89x and a current ratio of 1.22x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Suheung a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Suheung (008490) the key facts are: market cap ₩224.9B, P/E 4.6x, revenue ₩722.3B, 52-week range 16000-32600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Suheung's full fundamentals live
Get Suheung's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.